Cart
sales@molnova.com
AG-09/1
CAS No. 356776-32-4
AG-09/1( —— )
Catalog No. M35209 CAS No. 356776-32-4
AG-09/1 is a selective and potent formyl peptide receptor 1 (FPR1) agonist that activates chemotaxis in human neutrophils.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 155 | In Stock |
|
| 10MG | 235 | In Stock |
|
| 25MG | 416 | In Stock |
|
| 50MG | 602 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAG-09/1
-
NoteResearch use only, not for human use.
-
Brief DescriptionAG-09/1 is a selective and potent formyl peptide receptor 1 (FPR1) agonist that activates chemotaxis in human neutrophils.
-
DescriptionAG-09/1 is a specific formyl peptide receptor 1 (FPR1) agonist. N-formyl peptide receptors (FPR) are important in host defense.
-
In VitroN-formyl peptides activate phagocytes through G protein-coupled receptors known as FPR. FPR1 was the first FPR cloned and encodes a high-affinity receptor for fMLF.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number356776-32-4
-
Formula Weight358.37
-
Molecular FormulaC16H14N4O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (697.60 mM; Ultrasonic )
-
SMILESCOc1ccc2nc(SCC(=O)Nc3ccc(cc3)[N+]([O-])=O)[nH]c2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Andrei I Khlebnikov, et al. Computational Structure-Activity Relationship Analysis of Small-Molecule Agonists for Human Formyl Peptide Receptors. Eur J Med Chem. 2010 Nov;45(11):5406-19.?
molnova catalog
related products
-
Cixutumumab
Cixutumumab (IMC-A12), a humanized monoclonal antibody targeting IGF-1R, exhibits high affinity and inhibits ligand-dependent receptor activation, impeding downstream signaling.
-
AZD0780
AZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone.
-
GIP (1-30) amide (Hu...
GIP (1-30) amide (Human) TFA is a glucose-dependent insulinotropic polypeptide fragment. Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions.
